With free membership for academic and early career scientists, students, industry and other stakeholders involved in biomedical research, members can interact online 24/7 as well as attend planned events, including open houses, roundtables and Helpathons.
A user-friendly website features up to date news, resources, tools, networking and project collaboration opportunities, latest research papers, job vacancies and academic openings. The community is curated by members and hosted by Animal Free Research UK coordinators.
Members are invited to create and add content to the online forum, share events and resources, and to collaborate on projects such as writing reviews, articles and much more. The Animal Free Research Community of Practice will bring scientists closer. It will raise awareness, deepen knowledge, drive creativity and spark passion for a science that benefits animals as well as humans.
We urge all who want to practice modern medical research – that which truly delivers benefits for human health – to sign up and become part of this important, exciting community.
The thalidomide tragedy shocked the world and led to new laws requiring ‘proof of safety’ in animals, despite the irony that it was thalidomide’s near-total safety in animals that helped to cause the tragedy and would not have prevented it. This new analysis shows that moving away from animal testing is limited not by scientific possibilities, but by historical precedents and persistent beliefs that animal tests will prevent future tragedies. No amount of animal testing can eliminate the risks inherent in introducing new drugs to the market. Regarding animal tests as the gold standard gives a false sense of security, which acts as a barrier to creating potentially safer medicines and leads to human health risks, as well as the use and killing of many animals without a sound scientific basis.
Greater public and political awareness of the risks to public health that result from a continued reliance on animal testing can contribute to a shift in paradigm toward increased reliance on human-based safety testing. For scientists and regulatory bodies to contribute effectively to the transition away from animal testing, it is important that they continually reflect upon, and highlight how, an (often implicit) belief in animal testing as the gold standard continues to affect research, education, regulations, funding practices, etc. This should include a critical reflection on the 3Rs paradigm, as well as the critical perspectives of scholars from the humanities and social sciences, all of which are needed to break free from the confines of the current paradigm.
On 28 and 29 June, Animal Free Research (AFR) held its 2022 conference on ‘Modernising Medical Research’, a welcome return to ‘in person’ events following the COVID-19 pandemic and several members of the Safer Medicines Trust team attended over both days.
The event had a very positive atmosphere, with the aim of exchanging knowledge and ideas in the transition towards modern, human relevant medical research to benefit public health. This aligns with the objective of the Safer Medicines Trust that patient safety can and must be improved by utilising better science.
Credit: Wyss Institute for Biologically Inspired Engineering, Harvard University
Day one provided a series of talks from experts across many areas of research, for example on advances in in vitro technologies such as 3D organoids (‘mini organs’) or ‘Organ on a Chip’ models (also called microphysiological systems, or MPS). As shown in the image above, these are small devices lined with microchannels containing human cells, fluids and tissues which can test responses to drugs or monitor the progress of disease, to provide better prediction of the human response than conventionally used (animal) methods. A keynote speaker was Dr. Don Ingber, the founding director of the Wyss Institute at Harvard University who pioneered MPS technology with the ‘Lung On A Chip’, first developed in 2010. Exciting advances in this technology over the last decade have resulted in many more models such as brain, liver and even the beating heart, ultimately working towards a ‘human on a chip’ to revolutionise drug discovery and disease research. Dr Ingber was also presented with an ‘Animal Free Research Pioneer’ Award.
Other talks presented human relevant methods that could be used to study brain tumours, liver disease and colorectal cancer and how such methods provide better translation from ‘bench to bedside’ when compared to animal models. One speaker for example, highlighted how the results of chemotherapy found in mice translate to humans less than 10% of the time. The importance of use of human tissue removed during surgery (which would otherwise be discarded) was also discussed.
The methods described above are just a few examples of what are also collectively termed ’New Approach Methodologies’, or NAMs. A common barrier to the use of NAMs is the misperception that any one technique is expected to replace a corresponding animal method. This has never been the case. Instead, combinations of many techniques, for example in silico, in vitro and data from studies in humans can be combined to provide human relevant answers to research questions, where animal models often fail or do not even exist. This important issue (among others) was discussed at day two of the AFR conference, which was a ’round table’ event, bringing together scientists, campaigners and lobbyists to discuss how to effectively communicate to the research industry, regulators, political audiences and the public on the need to modernise scientific research by shifting to NAMs and ‘human relevant science for humans’. The need for change is already recognised by many in industry. For example, thein vitrotoxicology testing market was valued at 8.3 billion US dollars in 2019 and is projected to be worth over 18 billion US dollars by 2027.
Safer Medicines Trust and AFR are founder members of the Alliance for Human Relevant Science, a collaboration of companies, charities and organisations launched in 2017 to accelerate awareness and use of human relevant approaches within industry and the scientific research community.
A new paper by Safer Medicines scientific consultant Rebecca Ram, Dr. Domenico Gadaleta of the Mario Negri Institute, Italy and Dr. Tim Allen of the MRC Toxicology Unit, Cambridge discusses the progress of in-silico methods in New Approach Methodologies (NAMs) as well as the increasing need for use of ‘big data’ and artificial intelligence (AI) approaches in safety testing and biomedical research.
In silico, or computer-based research methods continue to emerge as part of a robust 21st century public health strategy, vital to improving the efficiency of preclinical drug discovery, as well as safety testing in the chemicals industry. They can be used alongside other methods e.g., human-based in vitro (cell or tissue derived) models as components of human-relevant New Approach Methodologies (NAMs).
Despite resisting scientific scrutiny for decades, animal studies have, over the last twenty years, been revealed by systematic reviews to be poorly conducted and unreliable, with the result that humans have, on occasion, been seriously harmed. Such troubling exposures have prompted several initiatives to improve the quality of animal studies and their reporting, but these have had little impact so far on improving their translation to humans. Could it be that fundamental differences between species constitute an insurmountable problem for biomedical research? Given that transformative human relevant technologies such as organ-chips and organoids are now available, could now be the time for a new paradigm?
March 22: The All Party Parliamentary Group for Human Relevant Science launches their report in Parliament, entitled: BRINGING BACK THE HUMAN: TRANSITIONING FROM ANIMAL RESEARCH TO HUMAN RELEVANT SCIENCE IN THE UK. MPs say human relevant science is essential to medical progress, and make recommendations including the creation of a dedicated ministerial-level post to ‘lead an ambitious and detailed programme of work’ cutting across Government to drive the UK’s transition to human relevant science.
Evidence given to the APPG stressed that now is the time for government leadership to put the human first and modernise medical research.
It emerged during the inquiry that ‘funding for human relevant technologies represents just 0.02% of the total public expenditure on research and development.’ The group is therefore urging the Government to increase the funding of human relevant approaches by strategically diverting resources away from traditional animal-based approaches which have a high failure rate and directing funding to transformative human relevant technologies.
Read the report and/or a separate brief summary here:
Our Pharmaceutical Director, Dr Gerry Kenna, recently presented a virtual seminar on “In vitro models for assessment of drug-induced liver injury (DILI): a personal perspective” to the Liver Toxicity Working Group of the US regulator, the FDA. The illustrated talk is 45 minutes long and gives a valuable insight, from an expert with decades of experience, into the state of the art of drug safety testing to avoid the risk of DILI. DILI is an important cause of drug-related ill health, which can be serious and even fatal, and is a leading reason for failed development and use of many otherwise promising new drugs.
The talk is technical, so you may wish to focus just on the Summary in the final 7 minutes. Here, Gerry explains that numerous methods which use human-derived cells are available, and provide data that are much more useful than animal safety studies. Because DILI is complicated, no single method can be used and multiple endpoints need to be analysed. Gerry highlights that there is an urgent need for scientists to reach consensus on which assays to use and how best to analyse and interpret the data that they provide. There is also a need for strong regulatory guidance that requires in vitro methods be used to assess the risk of DILI, thus reducing the incidence of this serious but often avoidable adverse drug reaction.
Our Patron, Sir David Amess MP, was a great friend to the Alliance for Human Relevant Science, as well as to Safer Medicines. We are all devastated by his tragic loss and send our heartfelt condolences to his family. The volume of tributes being paid to Sir David goes to show what a wonderfully kind, caring and delightful human being he was.
He was a prominent spokesperson on health issues and served for 10 years on the House of Commons Health Select Committee. In 2012, he received the “Outstanding Achievement Award” at the Charity Champion Parliamentary reception, in recognition of his lifetime commitment to charitable work. He was a powerful champion of many good causes and had an unequalled backbench record for introducing new bills into law.
Sir David supported our work for many years, and on becoming our Patron, he said: “I am passionate about both human health and animal welfare, and I applaud Safer Medicines Trust for showing that there is no contradiction between the two, as we are so often led to believe.”
The availability of data from both preclinical and clinical studies of drugs is key to understanding the effectiveness and safety of any treatment before it is approved for use in patients. In a recent webinar our Director Dr Jan Turner, described why gaps in this data either through selective reporting or omission of significant data all together, can have profound effects on the decision-making of regulatory agencies and ultimately lead to unsafe drugs being placed on the market. Jan’s slides are available here.
“The future of medicines regulation in the UK” was the subject of a recent Westminster Health Forum meeting at which our Director, Dr Jan Turner described why innovation and the development of methods to ensure safe and effective medicines, is imperative for the UK. The talk drew on a previous meeting in July 2020 where Jan also spoke but included some reflections this time on lessons learned from the COVID pandemic which may be exploited to develop safer medicine, and post-Brexit opportunities for the UK regulatory body MHRA to support the approval and inclusion of human relevant methods into medicines testing. Dr Turner’s slides are available here..
Safer Medicines Trust was a partner in a world-first comparative study led by the US Evidence-based Toxicology Collaboration (EBTC) and the Norwegian Institute of Public Health.
The collaboration conducted a comprehensive comparison of the in vivo (animal and human) and in vitro tests currently available to assess drug safety and compared their findings against ‘real world data’ on adverse drug reactions. They focused on two diabetes drugs: troglitazone (Rezulin), which was withdrawn from the market due to severe and fatal liver toxicity and rosiglitazone (Avandia), which remains on the market in the US.
Neither drug indicated a strong hazard signal in either preclinical animal studies or human trials. In contrast, in vitro data (using human cells and tissues) found that Rezulin exhibited strong signals for off-target effects on the liver, while Avandia did not.
This world-first comparative approach found that preclinical animal and clinical human trials – despite being mandatory – did not predict Rezulin’s potential to cause harm. Tests on human cells and tissues could have clearly revealed the hazard, which caused hundreds of liver injuries and killed at least 63 people. Sophisticated human-relevant technologies now offer a new paradigm for preventing adverse drug reactions and saving patients’ lives.
Our research consultant Dr Pandora Pound recently guest edited a special issue of the journal ‘Animals’ entitled “Are Animal Models Needed to Discover, Develop and Test Pharmaceutical Drugs for Humans in the 21st Century?” The key question she posed is whether there is value in refining animal models for medical research, or whether these should be relinquished in favour of new, human-focused research approaches. The seven open access, scientific papers that attempt to address this question, including Dr Pound’s editorial, can be found below.
A new All-Party Parliamentary Group for Human Relevant Sciences held its first AGM on Tuesday 6th October 2020, with the aim of accelerating the development and uptake of human relevant life sciences in the UK.
The APPG will be a discussion forum for politicians, the human relevant life sciences sector, third sector groups, scientists and stakeholders to promote new approach methodologies that provide unique insights into human biology, transform our ability to understand human disease and can develop effective new medicines more quickly and without the use of animals.
Speaking at the launch, the APPG’s Chair and Safer Medicines Trust Patron, Labour MP Grahame Morris, said, “I am delighted to Chair the new All-Party Parliamentary Group on Human Relevant Science. The COVID-19 pandemic has demonstrated that the current approach to developing new treatments is simply not fast enough to meet humanity’s needs. We urgently need a moonshot to transition to new approach methodologies which promise to deliver safer and more effective medicines, more quickly and at less cost.”
APPG Vice Chair and Safer Medicines Trust Patron, Conservative MP Sir David Amess said, “I am thrilled to be Vice Chair of the new All-Party Parliamentary Group on Human Relevant Science. With the cancellation of the Autumn Budget, the Government now has more time to think about what it can do to provide much-needed financial support to boost growth in the human relevant life sciences sector and enable the UK to remain an innovative science superpower.
“As the country seeks a COVID-19 vaccine, this is the perfect time for parliamentarians to take seriously the growing evidence in favour of the pioneering human relevant medical research techniques that are replacing the outdated use of animals.”
For more information on the APPG, please contact us at 0300 302 0521 or email info@SaferMedicines.org
“The future for UK regulation of medicines, medical devices and clinical trials – transparency and public trust, safety and enforcement, and support for innovation” was the subject of a recent Westminster Health Forum meeting at which our Director, Dr Jan Turner described why innovation and the development of methods to ensure safe and effective medicines, is imperative for the UK now and importantly, post Brexit. A recording of the talk is here and Dr Turner’s slides are here
We are calling for a change of mindset and a clear timetable for regulatory change to enable accelerated development of medicines which are likely to be safer, more effective and cheaper, without the use of animals. Investment in human relevant science offers a golden opportunity to revitalise medical research, save money, create wealth and improve public health.
We find ourselves in a time of global health emergency, one that will challenge our healthcare, social fabric and economy for years to come. Hard choices today have been borne out of great and immediate need. Yet there are patterns emerging in the scientific response that will have far reaching consequences for how we progress medical science in the future.
Hosted by the Physicians Committee for Responsible Medicine, in conjunction with US Congresswoman Lucille Roybal-Allard, our Pharmaceutical Director, Dr Gerry Kenna, recently spoke on why “Human-relevant models are needed to understand and treat human COVID-19 disease” at PCRM’s Congressional hearing “Confronting COVID-19: A Briefing on Prioritizing Human-Based Research”. A recording of the event is here and Dr Kenna’s slides are here.
Coronavirus: we’ve never had a better opportunity to harness the power of human relevant approaches
Unprecedented research efforts are underway across the world to combat the covid-19 pandemic. Much of this work involves testing potential treatments or vaccines in various animal species, both for safety and effectiveness. What is the likelihood that these animal studies will help us to find a vaccine or treatment within the ambitious timescale of 12 to 18 months?
Send Rat Trap to your MP and let us know, to avoid duplication. The following MPs already have a copy: Maria Caulfield, Brendan Clarke-Smith, Yvette Cooper, Geoffrey Cox, Richard Drax, Caroline Lucas, Anthony Mangnall, Navendu Mishra, Grahame Morris. Include a cover letter, using our template if you need inspiration